{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:59:00Z","timestamp":1761238740668,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT9000198"],"award-info":[{"award-number":["GNT9000198"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40268-020-00306-3","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:02:35Z","timestamp":1588791755000},"page":"209-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-887X","authenticated-orcid":false,"given":"Christine","family":"Roder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9838-6471","authenticated-orcid":false,"given":"Eugene","family":"Athan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"306_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00775-009-0466-z","volume":"14","author":"S Jackson-Rosario","year":"2009","unstructured":"Jackson-Rosario S, Cowart D, Myers A, et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au\u2013Se adduct. J Biol Inorg Chem. 2009;14:507\u201319.","journal-title":"J Biol Inorg Chem"},{"key":"306_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrmicro2536","volume":"9","author":"BP Willing","year":"2011","unstructured":"Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011;9:233\u201343.","journal-title":"Nat Rev Microbiol"},{"key":"306_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2958.1998.00663.x","volume":"27","author":"B Dupuy","year":"1998","unstructured":"Dupuy B, Sonenshein AL. Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol. 1998;27:107\u201320.","journal-title":"Mol Microbiol"},{"key":"306_CR4","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/IAI.00147-12","volume":"80","author":"LJ Deakin","year":"2012","unstructured":"Deakin LJ, Clare S, Fagan RP, et al. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun. 2012;80:2704\u201311.","journal-title":"Infect Immun"},{"key":"306_CR5","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/nature07822","volume":"458","author":"D Lyras","year":"2009","unstructured":"Lyras D, O\u2019Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458:1176\u20139.","journal-title":"Nature"},{"key":"306_CR6","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/infdis\/jit068","volume":"207","author":"A Howerton","year":"2013","unstructured":"Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infections. J Infect Dis. 2013;207:1498\u2013504.","journal-title":"J Infect Dis"},{"key":"306_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/jac\/dkl553","volume":"59","author":"DM Musher","year":"2007","unstructured":"Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother. 2007;59:705\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"306_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/jac\/dkt347","volume":"69","author":"CH Chilton","year":"2014","unstructured":"Chilton CH, Crowther GS, Freeman J, et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother. 2014;69(2):451\u201362.","journal-title":"J Antimicrob Chemother"},{"key":"306_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/imj.13027","volume":"46","author":"JA Trubiano","year":"2016","unstructured":"Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J. 2016;46:479\u201393.","journal-title":"Intern Med J."},{"key":"306_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1042\/EBC20160062","volume":"61","author":"P Harnvoravongchai","year":"2017","unstructured":"Harnvoravongchai P, Pipatthana M, Chankhamhaengdecha S, et al. Insights into drug resistance mechanisms in Clostridium difficile. Essays Biochem. 2017;61:81\u20138.","journal-title":"Essays Biochem"},{"key":"306_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","volume":"53","author":"A AbdelKhalek","year":"2019","unstructured":"AbdelKhalek A, Abutaleb NS, Mohammad H, Seleem MN. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Agents. 2019;53:54\u201362.","journal-title":"Int J Antimicrob Agents"},{"key":"306_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1039\/B917141J","volume":"2","author":"SE Jackson-Rosario","year":"2010","unstructured":"Jackson-Rosario SE, Self WT. Targeting selenium metabolism and selenoproteins: novel avenues for drug discovery. Metallomics. 2010;2:112\u20136.","journal-title":"Metallomics."},{"key":"306_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015;15:13\u201320.","journal-title":"Drugs R D."},{"key":"306_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10787-007-0021-x","volume":"16","author":"WF Kean","year":"2008","unstructured":"Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008;16:112\u201325.","journal-title":"Inflammopharmacology"},{"key":"306_CR15","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1128\/JB.01370-06","volume":"188","author":"S Jackson","year":"2006","unstructured":"Jackson S, Calos M, Myers A, et al. Analysis of proline reduction in the nosocomial pathogen Clostridium difficile. J Bacteriol. 2006;188:8487\u201395.","journal-title":"J Bacteriol"},{"key":"306_CR16","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1128\/JB.00164-09","volume":"191","author":"S Jackson-Rosario","year":"2009","unstructured":"Jackson-Rosario S, Self WT. Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J Bacteriol. 2009;191:4035\u201340.","journal-title":"J Bacteriol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00306-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00306-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00306-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:12:28Z","timestamp":1620259948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00306-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00306-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"6 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the Australian Government, National Health and Medical Research Council (GNT9000198).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christine Roder and Eugene Athan have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}